文献速递药物相互作用特殊人群用药治疗药物监测与药物基因组学

用PBPK模型优化中国SLCO1B1基因多态人群瑞格列奈与厄贝沙坦给药

Using physiologically based pharmacokinetic modelling to optimize repaglinide and irbesartan dosing in Chinese population with SLCO1B1 polymorphism.
PubMed 文献 · Br J Clin Pharmacol · 2026-08-13

本研究建立瑞格列奈(REP)和厄贝沙坦(IRB)的生理药动学(PBPK)模型,模拟SLCO1B1 c.521T>C基因多态人群的DDI并预测REP暴露。模型预测SLCO1B1 c.521TT者合用300 mg IRB时REP暴露显著增加,建议REP提前2小时或延后4小时服用,或减至原剂量的60%-70%。

要点

  • SLCO1B1 c.521TT基因型患者合用300 mg厄贝沙坦时瑞格列奈暴露显著增加。
  • 可间隔给药:瑞格列奈提前2小时或延后4小时,AUC0-∞比值为0.90-0.97。
  • 或减量至原剂量的60%-70%,AUC0-∞比值为0.99-1.10。

核心结论

  • 成功建立REP和IRB的PBPK模型,能准确描述血药浓度-时间曲线、AUC、Cmax和Tmax。
  • 模型预测SLCO1B1 c.521TT基因型患者合用IRB时REP暴露显著增加,需调整给药方案。

研究设计与样本

  • 基于文献和实验室数据建立REP和IRB的PBPK模型,并用已发表临床研究数据评估模型。
  • 应用REP/IRB PBPK模型模拟SLCO1B1 c.521T>C基因多态人群的DDI并预测不同给药方案下REP暴露。

主要发现

  • REP/IRB PBPK模型能准确描述血浆浓度-时间曲线、AUC、Cmax和Tmax。
  • 与SLCO1B1 c.521TC基因型人群相比,SLCO1B1 c.521TT基因型人群合用IRB后REP暴露显著增加。

关键数值与推荐

  • SLCO1B1 c.521TT基因型患者合用300 mg IRB时,REP提前2小时或延后4小时服用,AUC0-∞比值为0.90-0.97。
  • SLCO1B1 c.521TT基因型患者合用300 mg IRB时,REP减至原剂量的60%-70%,AUC0-∞比值为0.99-1.10。

临床怎么用

  • 对SLCO1B1 c.521TT基因型患者,合用300 mg厄贝沙坦时建议调整瑞格列奈给药时间或剂量。
  • 可根据可用剂量规格选择提前2小时、延后4小时服用或减量至60%-70%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The first aim of this study was to develop physiologically based pharmacokinetic (PBPK) models for irbesartan (IRB) and repaglinide (REP) and then apply the REP/IRB PBPK model to describe the drug-drug interaction (DDI) of REP and IRB in the population with SLCO1B1 c.521 T > C gene polymorphism. Second, the REP/IRB model was used to predict REP exposure under different administration protocols and provide dose adjustment recommendations for the population with SLCO1B1 c.521 T > C gene polymorphism. METHOD: The PBPK model was developed from literature and laboratory data, some parameters in the PBPK model were optimized and data from published clinical studies were used to evaluate the PBPK model. RESULT: The REP/IRB PBPK model showed good performance for accurately describing the plasma concentration-time profiles, area under the plasma concentration-time curve (AUC), maximum plasma concentrations (Cmax) and peak times (Tmax). The REP/IRB PBPK model predicted that, compared to the population with SLCO1B1 c.521TC genotype, in the population with SLCO1B1 c.521TT genotype, co-medicating with IRB significantly increased the exposure of REP. When co-administered with 300-mg IRB in patients with the SLCO1B1 c.521TT genotype, REP should be given either 2 h earlier or 4 h later (AUC0-∞ ratio: 0.90-0.97), or at 60-70% of the initial dose (AUC0-∞ ratio: 0.99-1.10), depending on available dosage strengths. CONCLUSION: A PBPK model was built for REP and IRB and used to predict DDI for the population with SLCO1B1 c.521 T > C gene polymorphism. Moreover, the model was applied to provide individualized drug recommendations for the SLCO1B1 c.521TT genotype population.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wen Y, Sun Z, Tan H, et al. Using physiologically based pharmacokinetic modelling to optimize repaglinide and irbesartan dosing in Chinese population with SLCO1B1 polymorphism. Br J Clin Pharmacol. 2026. PMID: 42595332. doi:10.1002/bcp.70784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。